VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program…. Read More
VANCOUVER, BC – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced that the first subject has been enrolled and dosed in… Read More
World’s First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC – Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that dosing… Read More
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is… Read More
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line data expected in the first half of… Read More
